Impact of T Cells on Age-related Vascular Dysfunction: A Translational Approach

Phase 1

Not yet recruiting

• Conditions: Cardiovascular Diseases; Inflammation; Aging

• Registration Number: NCT04344873
• Lead Sponsor: University of Utah

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-4-9
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Inclusion Criteria:<br><br> - Older adults (55-75 years old).<br><br> - Women will be at least two years postmenopausal, not using hormone therapy and have<br> a follicle stimulating hormone (FSH) concentration of >30 IU/L.<br><br>Exclusion Criteria:<br><br> - Autoimmune disorders,<br><br> - Hypertension (blood pressure >140/90mmHg),<br><br> - Body mass index of >30 kg/m2,<br><br> - Clinical CVD,<br><br> - Diabetes<br><br> - Current tobacco use,<br><br> - Regular aerobic exercise (>30 mins per day, > 2 days per week for the at least the<br> last 2 years),<br><br> - Current or recurring infections within 12 weeks of the baseline visit,<br><br> - A positive tuberculosis (TB) test or subjects at risk of TB,<br><br> - Positive test for Hepatitis B, C, or cytomegalovirus (CMV),<br><br> - Use of immunosuppressive medication,<br><br> - Vaccination within 4 weeks of the baseline visit,<br><br> - Major surgery within 8 weeks of the baseline visit,<br><br> - Previous lymphoid irradiation or bone marrow transplant,<br><br> - Subjects at risk for diverticulitis,<br><br> - Any laboratory test result that, in the opinion of the overseeing physician (Dr.<br> Frech) might place a participant at unacceptable risk.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in brachial arterial diameter after abatacept injection.;Change in brachial arterial flow rate after abatacept injection.

Secondary Outcome Measures

Name	Time	Method
Change in pulse wave velocity as measured by doppler ultrasound after abatacept injection.;Change in proportion of memory T-Cells after abatacept injection;Change in proportion of inflammatory biomarker Tumour Necrosis Factor alpha (TNF-a) after abatacept injection;Change in proportion of inflammatory biomarker Interferon gamma (IFN-?) after abatacept injection;Change in proportion of inflammatory biomarker interleukin 10 (IL-10) after abatacept injection;Change in proportion of inflammatory biomarker interleukin 17 (IL-17) after abatacept injection;Change in proportion of inflammatory biomarker forkhead box P3 (FoxP3) after abatacept injection;Change in proportion of inflammatory biomarker perforin after abatacept injection